Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial
- Authors
- Kang, Woong Chol; Kim, Minsu; Park, Sang Min; Kim, Byeong-Keuk; Lee, Byoung-Kwon; Kwon, Hyuck Moon
- Issue Date
- Nov-2020
- Publisher
- MDPI
- Keywords
- pitavastatin; contrast-induced nephropathy; chronic kidney disease
- Citation
- JOURNAL OF CLINICAL MEDICINE, v.9, no.11
- Journal Title
- JOURNAL OF CLINICAL MEDICINE
- Volume
- 9
- Number
- 11
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79212
- DOI
- 10.3390/jcm9113689
- ISSN
- 2077-0383
- Abstract
- This study aimed to evaluate the efficacy of pitavastatin pretreatment on contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) after a coronary procedure. This was a prospective, randomized, double-blinded, placebo-controlled, multicenter clinical trial. All consecutive 70 patients with CKD (eGFR < 60 mL/min/1.73 m(2)) were enrolled and randomized into two groups. Group I consisted of patients who were treated with statins (pitavastatin 4 mg/day) for seven days before and three days after the procedure (n = 37, 52.9%), and group II consisted of patients who were treated with a placebo (n = 33, 47.1%). The primary endpoint was the incidence of CIN, and the secondary endpoints were the change in serum creatinine ( increment sCr) level and estimated glomerular filtration rate ( increment eGFR) after the procedure. The mean age of the patients (males, 74%) was 70.4 +/- 9.0 years. After the coronary procedure, the incidence of CIN was lower in group I than in group II, but the difference was not significant (5.4% vs. 9.1%, p = 0.661). The maximal increment sCr was lower and the maximal increment eGFR was higher in group I than in group II, but the difference was not significant (-0.11 +/- 0.53 mg/dL and -0.04 +/- 0.33 mg/dL, p = 0.678; 4.3 +/- 11.2 mL/min/1.73 m(2) and -2.9 +/- 20.4 mL/min/1.73 m(2), p = 0.161, respectively). This study showed the possibility of a clinical benefit of pretreatment with a high dose of pitavastatin for the prevention of CIN in patients with CKD after coronary procedure (ClinicalTrials.gov Identifier: NCT01871792).
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/79212)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.